Two-year phase 3 GATHER2 results in 447 patients with geographic atrophy: avacincaptad pegol 2 mg reduced GA growth vs sham, by 14% monthly and 19% every other month (nominal P). Choroidal neovascularisation: 11.6% vs 9.0%.
RCTn = 447
Khanani et al. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial